Dapsone
Rash
AllerganSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Rash cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tetracycline Instituto Nacional de Cancerologia de Mexico | Phase 2 | B |
Irinotecan Amgen | Phase 2 | B |
Arestin British Columbia Cancer Agency | Phase 2 | B |
PANITUMUMAB Amgen | Phase 2 | B |
Same molecule, other indications
Dapsone is also rated in:
Cetuximab-induced Papulopustular (Acneiform) Rash Who HaveDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →